Premature Ejaculation Treatment Market Size 2024-2028

The Premature Ejaculation Treatment Market size is estimated to grow by USD 1.46 billion at a CAGR of 8.78% between 2023 and 2028. It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario. The market is dominated by off-label drugs, generic versions of patent-expired drugs, and over-the-counter formulations. The increasing demand for several off-label drugs is the primary factor driving the growth of the premature ejaculation (PE) treatment market. In addition, some clinical studies have demonstrated that combining PDE5 inhibitors with SSRIs provides better results in the treatment of premature ejaculation than using SSRIs alone because the improved erection resulting from the PDE5 inhibitor inhibits ejaculation through the downregulation of the receptors involved in somatosensory latency times. Irrespective of the mechanism, PDE5 inhibitors have been found to be safe and effective as a therapeutic adjunct for premature ejaculation in men. Therefore, the high efficacy of these drugs increases their demand among end-users, which will thereby contribute to the growth of the market during the forecast period.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation 

By Route Of Administration

The market share growth by the oral segment will be significant during the forecast period.  The significant market share of the oral route segment can be attributed to the popularity and high preference for oral medication as the first line of treatment for premature ejaculation, owing to its ease of use and wide availability. These drugs are available in different forms, such as tablets, capsules, and liquids.

Get a glance at the market contribution of various segments View a PDF Sample

The oral segment was the largest and was valued at USD 1.36 billion in 2018.  SSRIs were then used due to their sustained efficacy on ejaculatory latency and tolerable side effect profile. The mechanism for delayed ejaculation with SSRIs probably relates to the inhibition of multiple descending pathways associated with the ejaculatory reflex. This is supported by studies that show significant variations in cortical serotonergic function between patients with premature ejaculation in males. However, the non-availability of approved oral drugs to treat premature ejaculation in the US is attracting many large pharmaceutical companies to capitalize on the market by investing in R&D programs and developing new solutions. Such factors are expected to drive the growth of the oral segment in the market in focus during the forecast period.

By Drug Class

Selective serotonin reuptake inhibitors (SSRIs) are a commonly used drug class for premature ejaculation treatment. These drugs can be taken alone or in combination with other drug classes, such as antidepressants. Being the most common drug form for the disease, SSRIs have the largest market share in the premature ejaculation (PE) treatment market. SSRIs such as fluoxetine, paroxetine, and sertraline have been gaining traction among users. The side effects caused by the long-term use of SSRIs are an important point of concern and must be considered by both the patient and the physician. Some of the adverse effects of the drug class are neurologic and psychiatric sequelae, fluctuations in body weight, dermatologic reactions, cognitive impairment, anticholinergic effects, and sexual side effects other than premature ejaculation, such as loss of libido and erectile dysfunction. The side effects caused by these drugs are expected to act as a major challenge to the growth of this segment of the market in focus during the forecast period.

The lack of approved premature ejaculation drugs in the US by regulatory bodies such as the US Food and Drug Administration (FDA) has propelled the popularity of PDE5 inhibitors, which will drive the premature ejaculation treatment market. However, clinical studies show that sildenafil does have several side effects, which promotes its use in treating premature ejaculation and improving male sexual performance. Vardenafil Vardenafil, a selective inhibitor of cGMP-specific PDE 5, is an oral medication to treat erectile dysfunction in men. It was approved by the US FDA in 2003 for the treatment of erectile dysfunction. The drug has been used regularly as a solution to delay ejaculation for satisfactory sexual intercourse. Thus, the growing popularity of PDE5 inhibitors for the treatment thereby will drive the growth of this segment in the market during the forecast period.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominates the market, primarily due to a significant rise in the number of premature cases, owing to psychological strain and stress from an ever-changing lifestyle. Additionally, an increase in the number of premature ejaculation cases will be addressed through a broad range of products in the pipeline. Increased R&D spending will further boost the growth of the regional market. Therefore, such factors are expected to drive the growth of the regional market during the forecast period.

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

A. Menarini Industrie Farmaceutiche Riunite Srl - The company offers premature ejaculation treatments such as Priligy and Spedra.

• Absorption Pharmaceuticals LLC
• Alembic Pharmaceuticals Ltd.
• Amneal Pharmaceuticals Inc.
• Aytu BioPharma Inc.
• Bayer AG
• Eli Lilly and Co.
• Futura Medical plc
• GlaxoSmithKline Plc
• Johnson and Johnson
• LloydsPharmacy
• Morari Inc.
• NeuroHealing Pharmaceuticals Inc.
• Niksan Pharmaceutical
• Pfizer Inc.
• Plethora Solutions Ltd.
• Prinston Pharmaceutical Inc.
• Ralington Pharma LLP
• Sunrise Remedies Pvt. Ltd.
• Tabuk Pharmaceuticals

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

Premature ejaculation (PE) is a common sexual health issue, encompassing rapid ejaculation and early ejaculation, leading to sexual encounter dissatisfaction. Both lifelong PE and acquired PE pose challenges, but behavioral techniques and medical assistance offer relief. Diagnostic methods aid in personalized treatment planning, with medications like Dapoxetine and Westoxeti extending sexual pleasure duration. However, concerns such as nausea and travel restrictions persist, necessitating ongoing clinical trials to enhance premature ejaculation treatment efficacy. There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

Increasing demand for topical drug therapies is notably driving the market growth. Premature ejaculation remains an underdiagnosed and undertreated disease process, with limited data available on potential underlying mechanisms and long-term outcomes of treatment options. It is among the most common sexual dysfunctions that affect men. Topical therapies that are commonly used result in prolonged intravaginal ejaculatory latency time at the expense of potential penile/vaginal hypotheses.  

Further, a topical lidocaine-prilocaine-containing spray (FORTACIN) has been developed, with initial results demonstrating a 6.3-fold increase in the intravaginal ejaculatory latency time and an associated improvement in patient-reported outcome measures of control and sexual satisfaction. However, as topical aerosol has minimal local and negligible systemic side effects, they are in high demand for the treatment of prematurely. Therefore, the advantages offered by topical therapies are expected to increase their demand, which will thereby drive the growth of the market during the forecast period.

Significant Market Trends

The advent of nanotechnology in premature ejaculation treatment drugs is an emerging trend shaping the market growth. Nanotechnology was first introduced in the 1980s. Since then, it has provided researchers with new approaches to developing drug delivery systems for various diseases. Many nanotechnology-associated novel technologies have been brought into clinical use in the past decades, and uncountable patients have benefited from them, which convinces the researchers of a bright prospect of nanotechnology in the field of medicine. With the application of nanotechnology, researchers have explored new approaches to medicine delivery to promote efficacy and minimize the side effects of the currently available agents for premature ejaculation.

For instance, a study conducted by Han et al. demonstrated that nanoparticles represent a potential novel route for the topical delivery of erectogenic agents, which could improve the safety profile of the existing orally administered drugs by avoiding the effects of absorption and first-pass metabolism and would be less hazardous than injection. Therefore, nanotechnology has provided researchers with new approaches to developing a drug delivery system, which is expected to contribute to the growth of the market during the forecast period.

Major Market Challenges

The availability of alternative treatment options for premature ejaculation is a significant challenge hindering market growth.  While the premature ejaculation treatment market has limited approved products, the growing number of premature ejaculation cases globally has led to an increase in the number of alternative treatment methods for the disease.

In addition, various behavioral therapies are useful in patients with premature ejaculation, which include masturbation before coitus (pre-coital masturbation), stop-start and squeeze techniques, the use of multiple condoms, and pelvic floor exercises.  Moreover, the growing popularity of these alternative premature ejaculation treatment options has resulted in the diminished growth of authentic pharmacological therapies offered by various pharmaceutical companies, thus will pose a threat to the market in focus growth during the forecast period.

Buy Now Full Report and Discover More

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Segment Overview

The market forecasting report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments

• Route Of Administration Outlook 
  • Oral
  • Topical

• Drug Class Outlook 
  • SSRIs
  • PDE5 inhibitors
  • Amide anesthetics
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina
    • Australia

Market Analyst Overview:

Premature ejaculation (PE) is influenced by various psychological and biological factors, including early sexual experiences, sexual abuse, poor body image, depression, anxiety, and hormone levels. While inflammation or infection of the prostate or urethra can contribute, several treatments are available. These include pharmaceutical options like Tramadol hydrochloride, behavioral therapy, psychological counseling, and lifestyle modifications. Diagnostic tools aid in assessment, with FDA-approved devices like Promescent offering solutions. Collaboration between pharmaceutical companies like Teva, Sunrise Pharma, and Torrent Pharma and healthcare providers such as Kaiser Permanente drives research and clinical trials. Despite challenges like resource shortages and delays, advancements in telemedicine and digital health platforms offer hope in addressing this prevalent condition.

Further, pemature ejaculation (PE) is a complex condition influenced by various factors, including psychological elements and inherited traits. Treatment options continue to expand with the development of new drugs and devices. Zertane, an example of such innovation, has undergone clinical trials and received FDA approval as an effective therapy. Collaborations between pharmaceutical companies and healthcare providers are vital in advancing research and enhancing treatment options. The prevalence rate of PE underscores the importance of such developments. Pharmaceutical treatments, combination therapies, and interventions, including the use of analgesics and local anesthetics, aim to address the condition's multifaceted nature. These therapies can be accessed through various channels, including hospitals, retail pharmacies, and telemedicine platforms. Despite advancements, challenges like limitations in current therapeutics persist, emphasizing the ongoing need for innovation in this field.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch